Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05095168
Other study ID # CAN106-HV-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 22, 2021
Est. completion date November 30, 2021

Study information

Verified date May 2022
Source CANbridge Life Sciences Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106 injection.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date November 30, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 45 Years
Eligibility Inclusion Criteria: - Subjects must be able to understand and provide informed consent. - Males or females, between 21 and 45 years of age, inclusive; - Body mass index must be within the range of 18.5 to 32.0 kg/m2; - 12-lead electrocardiogram (ECG) within normal limits with no clinically significant abnormalities in the opinion of the Investigator; - Systolic blood pressure =140 mmHg and a diastolic blood pressure of = 90 mmHg after 5 minutes with supine rest; - non-pregnancy - meningococcal vaccinations for at least 2 weeks before dosing Exclusion Criteria: - Disease or conditions interfere with participating the trial - Active serious mental illness or psychiatric disorder - clinically relevant abnormal test results in hepatic function - unacceptable CBC lab test - asymptomatic complement deficiency - Any other clinical safety laboratory test - HIV, HBV, HCV positive - Alcohol and drug abuse - etc.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CAN106
CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
Placebo
placebo

Locations

Country Name City State
Singapore National University Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
CARE Pharma Shanghai Ltd.

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of subjects with dose-limiting toxicity (DLTs) TEAEs will be categorized as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria.
a DLT is defined as one subject with a Grade 3 AE or higher, that are assessed as drug-related by the site investigator.
6-months after dosing
Primary Incidence of adverse events (AEs) An AE is defined as any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. 6-months after dosing
Primary Incidence of severe adverse events (SAEs) Any untoward medical occurrence that at any dose:
Results in death,
Is life-threatening,
Requires inpatient hospitalization or prolongation of existing hospitalization,
Results in persistent or significant disability/incapacity, or
Is a congenital anomaly/birth defect. (ICH E6 (R2))
6-months after dosing
Secondary PK parameters - tmax time to reach maximum of concentration (days) 6-months after dosing
Secondary PK parameters-Cmax peak plasma concentration 6-months after dosing
Secondary PK parameters - AUC0-t Area under the plasma concentration versus time curve to the last visit (AUCt) 6-months after dosing
Secondary PK parameters - t1/2 terminal elimination half-life 6-months after dosing
Secondary PD endpoints-free C5 maximal change from baseline in free C5 concentrations at each of scheduled post baseline assessment time-points (µg/ml); 6-months after dosing
Secondary PD endpoints-CH50 maximal change from baseline total complement activity (CH50) at each of scheduled post baseline assessment time-points (%); 6-months after dosing
Secondary PD endpoints-total C5 meausure the absolute change from baseline in total C5 concentrations at each of scheduled post baseline assessment time-points (µg/ml); 6-months after dosing
Secondary Immunogenicity Anti-drug Antibody (ADA) titers 6-months after dosing
See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Completed NCT02598583 - Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1/Phase 2
Recruiting NCT05539248 - A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH Phase 1/Phase 2
Active, not recruiting NCT03460301 - Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH N/A
Completed NCT01412047 - Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study N/A
Completed NCT02605993 - Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Terminated NCT04702568 - A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05337683 - A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
Active, not recruiting NCT03531255 - Pegcetacoplan Long Term Safety and Efficacy Extension Study Phase 3
Not yet recruiting NCT06449001 - Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis Phase 3
Completed NCT03593200 - A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH Phase 2
Completed NCT05884060 - Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
Available NCT05982938 - Danicopan Early Access Program